Brought to you by:
Elucid launches PlaqueIQ image analysis software for carotid arteries
Elucid has announced the launch of its PlaqueIQ image analysis software for the quantification and classification of plaque morphology in the carotid arteries. According to the company, as the “first and only” computed tomography (CT)-based plaque analysis software indicated for the…
PROMISE III: Six-month data ‘reinforce’ case for TADV in no-option CLTI patients
Six-month outcomes among no-option chronic limb-threatening ischemia (CLTI) patients treated using transcatheter arterialization of the deep veins with the LimFlow system (Stryker/Inari Medical) in the PROMISE III trial showed a 81% rate of amputation-free survival. Principal investigator Daniel Clair, MD,…
PERFORMANCE III demonstrates ‘very low’ 30-day event rates for dual neuroprotection in TCAR
Thirty-day results from the PERFORMANCE III study of integrated embolic protection (IEP) in transcarotid artery revascularization (TCAR) demonstrate “very low” 30-day event rates. Sean Lyden, MD, chair of vascular surgery at the Cleveland Clinic in Cleveland, Ohio, shared this finding…
‘Excellent’ one-year outcomes from ROADSTER 3 show TCAR is ‘safe and effective’
One-year outcomes in the ROADSTER 3 post-approval study to evaluate the safety and effectiveness of transcarotid artery revascularization (TCAR) using the Enroute stent and neuroprotection system (Boston Scientific) in standard-surgical-risk patients revealed a 1.5% intention-to-treat rate of composite major adverse…
One-year results from IVC stent clinical trial show positive safety and efficacy data
Twelve-month results from the clinical trial assessing a dedicated venous stent for the treatment of symptomatic inferior vena cava (IVC) obstruction with or without combined iliofemoral obstruction showed the device exceeded its performance goal for freedom from a composite of…
InterVene receives US FDA 510(k) clearance for Recana thrombectomy system
InterVene recently announced it has received 510(k) clearance from the US Food and Drug Administration (FDA) for the Recana thrombectomy catheter system, which is designed for the treatment of venous in-stent restenosis and native vessel obstructions. A press release notes…
Vein mapping rates show no sign of change two years after BEST-CLI, new study demonstrates
Vein mapping for lower extremity bypass in patients with chronic limb-threatening ischemia (CLTI) remains unchanged two years after the BEST-CLI, “revealing the difficulty in changing practice patterns based on new evidence,” according to the authors behind a new retrospective multicenter…
Anton Sidawy becomes president of American College of Surgeons
Former Society for Vascular Surgery (SVS) President Anton N. Sidawy, MD, FACS, DFSVS, became the 106th president of the American College of Surgeons (ACS) at the ACS Clinical Congress 2025 in Chicago earlier this month (Oct. 4–7). A professor of…
‘Ask not what vascular surgery can do for you… ask what it can do to you’
During his own recent presidential address on home turf, Patrick Muck, MD, invoked immortable words from the inaugural address of President John F. Kennedy to make a very serious point about radiation safety in vascular care: “Ask not what vascular…
Randomized data ‘debunks’ widely used negative pressure wound therapy
“How did an ineffective and costly intervention become routine care in the NHS [UK National Health Service]?” Ian Chetter, MBChB, chair of surgery at Hull York Medical School, University of Hull in Hull, England, posed at the 39th European Society…